Gunggung dhuwit awis saben saham Natera Medical (NTRA)

Natera, Inc. (NTRA) is based on unique genomic data and proprietary DNA analysis. The estimated cash per share demonstrates current liquidity, with the value of 7.63 characterizing this level. Management's aggressive strategy ensures rapid revenue growth, while the focus on in-house R&D and patent protection eliminates the need for mergers with other players.
Rincian analitis perusahaan Natera, Inc.
- rega pasar lan target rega analis:
- rincian kapitalisasi pasar:
- indikator nilai aset resik miturut neraca:
- informasi babagan utang lan solvabilitas:
Koefisien Total Utang marang Modal Natera, Inc.|NTRA - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang modal Natera|NTRA - Gunggung utang perusahaan|Utang marang nilai buku Natera Medical|NTRA - Kewajiban jangka dawa perusahaan|Gunggunge utang jangka cendhak Natera|Rasio likuiditas darurat natera.com
- data bathi resik lan rasio valuasi:
NTRA - Penghasilan resik|Bathi resik mangsa ngarep Natera, Inc.|NTRA - Rasio rega marang bathi|Pangali mangsa ngarep rega marang bathi Natera, Inc.|NTRA - Pangali PEG|Pangali EV/EBITDA Natera Corp|NTRA - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajroning taun lumaku Natera|NTRA - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan natera.com|NTRA - Wutah bathi saben saham ing taun lumaku|Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep Natera, Inc.
- rincian pendapatan lan dodolan emiten:
NTRA - Pendapatan perusahaan|Pendapatan mangsa ngarep perusahaan Natera Medical|NTRA - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Natera Inc|NTRA - Wutah dodolan YoY (TTM)|Wutah dodolan kuartal marang kuartal Natera|NTRA - Nilai perusahaan marang pendapatan
- informasi babagan tingkat margin:
- rincian posisi dhuwit lan arus kas:
Ringkesan analisis perusahaan:NTRA Natera, Inc.

This indicator determines the volume of liquid assets per common share, allowing for an assessment of the internal capital cushion and investor protection. Analyzing the average cash per share reveals how explosive demand for Natera, Inc. (NTRA) oncology tests has transitioned the company from depleting reserves to self-funding via positive operating cash flow.